Fluoroquinolones as anti-HCV drugs
Phase 1
- Conditions
- Hepatitis C virus infection.Chronic viral hepatitis C
- Registration Number
- IRCT2014102619678N1
- Lead Sponsor
- Higher Education Commission, Pakistan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
•Patient on IFN treatment who have not shown two-log reduction in their HCV load for 3 months
•HCV-RNA positive
•Infection with HCV genotype 3a
•Chronic hepatitis diagnosed by liver ultrasound
•Pre-cirrhotic, as determined by liver ultrasound
•Informed consent to participate in the study
Exclusion criteria:
•Known hypersensitivity to fluoroquinolones
•Infection with HCV genotype other than 3a
•Pregnant females
•Concurrent hepatitis B or HIV infection
•Carcinomatous changes on liver biopsy evident in liver ultrasound
•History of alcohol or intravenous drug abuse
•Disinclination to informed consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral load. Timepoint: 3 months post drug treatment. Method of measurement: Quantitative Real Time PCR for viral RNA.
- Secondary Outcome Measures
Name Time Method iver function test and Complete Blood Count. Timepoint: Weekly throughout the drug treatment. Method of measurement: Clinical laboratory using automated testing units and microscopy.